Thermo Fisher Scientific Inc. announced plans to invest an additional $2 billion in the United States over the next four years, aiming to strengthen American innovation, manufacturing, and economic competitiveness within the life sciences sector. This investment is a strategic response to potential impacts from U.S.-China tariffs and policy shifts.
The $2 billion investment includes $1.5 billion in capital expenditures to expand U.S. manufacturing facilities and an additional $500 million in research and development. As one of the largest manufacturers of medicines globally, Thermo Fisher's expanded domestic capacity will support a more resilient U.S. healthcare supply chain.
Marc N. Casper, chairman, president, and chief executive officer, emphasized the company's commitment to U.S. manufacturing, ensuring that life-saving medicines and therapies will continue to be developed and produced in America for decades to come. This builds on Thermo Fisher's existing footprint of 64 U.S. manufacturing operations across 37 states and its annual $1 billion R&D investment in the U.S.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.